Placental immune editing switch (PIES): learning about immunomodulatory pathways from a unique case report
Open Access
- 11 November 2016
- journal article
- case report
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (50) , 83817-83827
Abstract
The hypothesis of this work is that, in order to escape the natural immune surveillance mechanisms, cancer cells and the surrounding microenvironment might express ectopically genes that are physiologically present in the placenta to mediate fetal immune-tolerance. These natural “placental immune-editing switch” mechanisms (PIES) may represent the result of millions of years of mammalian evolution developed to allow materno-fetal tolerance. Here, we introduce genes of the immune regulatory pathways that are either similarly over- or under-expressed in tumor vs normal tissue. Our analysis was carried out in primary breast cancer with metastatic homolateral axillary lymph nodes as well as placenta tissue (both uterine decidual tissue and term placenta tissue) from a pregnant woman. Gene expression profiling of paired non-self and self tissues (i.e. placenta/uterus; breast cancer/normal breast tissue; metastatic lymphnode/normal lymphnode tissue) was performed using the PanCancer Immune gene panel, a 770 Nanostring gene expression panel. Our findings reveal overlapping in specific immune gene expression in placenta and cancer tissue, suggesting that these genes might play an important role in maintaining immune tolerance both physiologically (in the placenta) and pathologically (in the cancer setting).Keywords
This publication has 38 references indexed in Scilit:
- Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpectedJournal of Clinical Investigation, 2015
- Human Chorionic Gonadotropin as a Central Regulator of Pregnancy Immune ToleranceThe Journal of Immunology, 2013
- Direct multiplexed measurement of gene expression with color-coded probe pairsNature Biotechnology, 2008
- Expression of CD28 and cytotoxic T lymphocyte antigen 4 at the maternal-fetal interface in women with unexplained pregnancy lossInternational Journal of Gynecology & Obstetrics, 2006
- A critical role for the programmed death ligand 1 in fetomaternal toleranceJournal of Experimental Medicine, 2005
- CTLA-4 Blockade: Unveiling Immune RegulationJournal of Clinical Oncology, 2005
- Dendritic Cell Function in Vivo during the Steady State: A Role in Peripheral ToleranceAnnals of the New York Academy of Sciences, 2003
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Prevention of Allogeneic Fetal Rejection by Tryptophan CatabolismScience, 1998
- Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptusThe Journal of Immunology, 1997